Mylan NV has not settled with the U.S. Department of Justice over the classification in the Medicaid program of its life-saving allergy treatment EpiPen, said Andrew Slavitt, acting head of the Centers for Medicare & Medicaid Services. Mylan said in October that it would pay $465 million to settle questions over whether it underpaid U.S. government healthcare programs.